Stay current with the latest news on Blood Cancer United research programs, FDA approvals, research grants and awards, the Therapy Acceleration Program, Beat AML and other clinical research programs, and more.
News
FDA OKs the First All-Oral, Time‑Limited Treatment Option for Adults Newly Diagnosed with Most Common Form of Leukemia
A major focus of Blood Cancer United's work is supporting time‑limited treatments like this new acalabrutinib approval that are effective but do not r…
News
FDA Expands CAR T Approval to Include Patients with Rare, Aggressive Type of Non-Hodgkin Lymphoma
Blood Cancer United provided funding for the clinical trial that led to the original approval of axi-cel through its Therapy Acceleration Program® and…
News
FDA Approves Combination Therapy for Newly Diagnosed Multiple Myeloma
“This approval represents an important step forward for people who are newly diagnosed with this disease,” said Lore Gruenbaum, Ph.D., Chief Scientifi…
News
Blood Cancer United Expands its Beat AML® Master Clinical Trial Advancing Next-Generation Treatment
In collaboration with AVEO Oncology, an LG Chem company, (“AVEO”) the new Beat AML sub-study is evaluating ficlatuzumab, a monoclonal antibody targeti…
News
FDA Approval Increases Access to a Follicular Lymphoma Immunotherapy
The FDA approves Lunsumio VELO™, a one-minute injection for relapsed follicular lymphoma, showing strong response rates and improved patient access.
News
FDA Expands Use of Targeted Therapy for Most Common Leukemia in Adults
The FDA this week approved pirtobrutinib (Jaypirca®) for the treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in ad…
News
FDA Approves First CAR T-Cell Immunotherapy for Marginal Zone Lymphoma
Liso-cel (Breyanzi®) is now approved to treat five types of blood cancer
News
FDA Expands Drug’s Approval To Include More People With AML
Blood Cancer United funding supported discovery and development of breakthrough menin inhibitors.
News
Blood Cancer United Showcases Bold Research and Vision at 2025 ASH Annual Meeting
Data from Master Clinical Trials—focused on transforming care for patients with acute myeloid leukemia—will be presented at ASH.
News
FDA Approves Targeted Immunotherapy for Adults with Follicular Lymphoma
“Although we are making great progress in treating follicular lymphoma, it remains incurable, and we need new treatments like epcoritamab in this chem…
News
FDA approves new drug to treat advanced AML in adults
Blood Cancer United® funding supported menin inhibitor drugs, including ziftomenib, at every stage of scientific development.
News
FDA Approves Drug for People With Advanced Disease Multiple Myeloma
Belantamab mafodotin (Blenrep) in a three-drug combination is now approved for the treatment of relapsed/refractory multiple myeloma.
